Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.37, moving +1.51% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.28%. Elsewhere, the Dow ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article ...

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors should ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...

Recursion Pharmaceuticals has agreed to acquire the Oxford, U.K.-based artificial intelligence (AI) drug pioneer Exscientia, the companies said today, in a deal that consolidates two leaders in ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...